Effects of memanthine in traumatic brain injury

Neuroprotective effects of memanthine in patients with traumatic brain injury

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013022610178N4

Enrollment

Registered

2013-05-07

Start date

2013-05-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

traumatic brain injury. intracranial injury

Interventions

Memantine 20 mg three times per day for 7 days.

Treatment - Drugs

Memantine 20 mg three times per day for 7 days

Eligibility

Sex/Gender

All

Age

18 Years to 149 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: all patients with traumatic brain injury exclusion criteria: hemorrhagic stroke; sensitivity to memantine; acute or chronic renal failure; acute or chronic hepatic disease; acute MI (<48 hours); autoimmune diseases; administration of memantine during 6 months before stroke

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Neuron specific enolase. Timepoint: Day 1,3,5. Method of measurement: Elisa kits.	—

Secondary

Measure	Time frame
Glasgow Coma scale. Timepoint: fraom day 1 for 7days. Method of measurement: Examination.;Mortality. Timepoint: 90 days after trauma. Method of measurement: Will be checked by phone.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Sistanizad

Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences

sistanizadm@sbmu.ac.ir+98 21 8820 0087

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026